Theravance Biopharma TBPH
TBPH
$17.03 +0.00 (+0.00%)
At close: Sep 25, 2026 · 4:00 PM EDT

Theravance Biopharma (TBPH) Long-Term Debt Repayments (2020 - 2021)

Updated

Theravance Biopharma's Long-Term Debt Repayments came in at $631.6 million for FY2022, compared with $10.73 million in FY2021.

Analysis

Theravance Biopharma (TBPH) Long-Term Debt Repayments (2020 - 2021) Analysis & Trends

Going back to FY2012, Theravance Biopharma's Long-Term Debt Repayments data covers 5 years.

  • Long-Term Debt Repayments carries a three-year compound annual growth rate of 564.6% (FY2019 to FY2022).
  • The FY2022 figure represents the highest annual Long-Term Debt Repayments in data going back to FY2012.
  • Per Business Quant, earlier years put Long-Term Debt Repayments at $10.73 million in FY2021 (-95.4%), $235.35 million in FY2020 and $2.15 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 1.00 Mn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 2.00 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 2.46 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 17.00 Mn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Theravance Biopharma 883.70 Mn -543.66 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 5.03 Mn
Mar 31, 2021 5.70 Mn
Mar 31, 2020 235.35 Mn
API Access

Theravance Biopharma Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=TBPH&period=max&api_key=YOUR_API_KEY